



**LA**  
**B**IOSCIENCE  
**E**COSYSTEM  
**S**UMMIT  
**T**WENTY23™

**UCLA**

**THURSDAY**  
**MAY 25, 2023**

**UCLA MEYER AND RENEE LUSKIN  
CONFERENCE CENTER**

# SPONSORS

## INNOVATOR SPONSOR



## UCLA GOLD SPONSOR



## BRUIN BLUE SPONSOR



## REGIONAL SPONSOR



## UCLA BEAR SPONSOR




## MEDIA SPONSOR



## COMMUNITY PARTNER





# WELCOME

Dear LABEST Attendees,

UCLA Technology Development Group welcomes you to the 5th Annual LABEST conference. This year's event marks a year of growth for the life science industry in our region and our event becoming the industry's leading summit in Southern California.

We built LABEST as an international showcase for doing business in our region, as part of our global outreach. We are pleased to host Director General Daren Tang from the UN World Intellectual Property Organization and Dr. Albert Bourla Chairman and CEO of Pfizer as our keynote speakers.

The UC system has always been a strong collaborator translating scientific ideas, concepts and invention to various products. Cutting edge science performed in labs on UC campuses across California is making a positive impact on people lives throughout the world. I am excited that Regents Board Chair Leib, Regent Park and Chancellor Block, will speak in a fireside chat on how academia plays an important role in the bioscience ecosystem and how the UC system plans to be at the cutting edge of this process.

In addition to our blockbuster panels featuring leaders of the industry and local hospitals, there will be dozens of scientific presentations, startups pitches, VC panel and infrastructure spotlights.

We are grateful to our sponsors especially to our partnership with Amgen and Kite. Thank you for being a part of this exceptional day.



**Amir Naiberg**

Associate Vice Chancellor, CEO & President  
UCLA Technology Development Group

**#LABEST2023 | [tdg.ucla.edu](https://tdg.ucla.edu)**

## MEETING SPACE: LEVEL 1



Centennial Ballroom  
**MORNING: Main Track**  
**AFTERNOON: Research Theme Showcases**

**Lunch**  
 UCLA TECHNOLOGY DEVELOPMENT GROUP  
**Patio**

**Cappuccino Connection**

**WiFi Access**  
 NETWORK: **Luskin\_Meeting**  
 (include underscore)  
 PASSWORD: **LCC2023**


**To Parking Structure 8**

**Video Interview**

**VIP/Speaker Green Room**

**Lunch** **Charging Stations** **Lounge** **Refreshment Stations** **Exhibitors**  
 Complimentary drinks and snacks

## MEETING SPACE: LEVEL 2



# Our Mission: To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

To learn more visit [www.amgen.com](http://www.amgen.com).



**AMGEN**



## TABLE OF CONTENTS

<b>Welcome — Amir Naiberg</b>	<b>3</b>
<b>Luskin Conference Center Maps</b>	<b>4</b>
<b>Main Track (morning)</b>	<b>9</b>
<b>UCLA TDG Learning Lounge</b>	<b>11</b>
<b>Startup Ecosystem Showcase</b>	<b>12</b>
<b>Nucleate and UCLA PDA Showcase</b>	<b>13</b>
<b>Nucleate Pitch Showcase Company Summaries</b>	<b>14</b>
<b>LA Biomanufacturing Showcase</b>	<b>15</b>
<b>Non-Dilutive Funding Seminar</b>	<b>16</b>
<b>Research Showcase A</b>	<b>17</b>
<b>Research Showcase B</b>	<b>18</b>
<b>Research Showcase C</b>	<b>19</b>
<b>LABEST 2023 Exhibitors</b>	<b>20</b>
<b>Featured UCLA Technologies</b>	<b>21</b>
<b>Sponsors</b>	<b>28</b>

## WELCOME

**Thursday, May 25, 2023**  
 UCLA Meyer and Renee Luskin  
 Conference Center

## SPECIAL SERVICES



**The Cappuccino Connection**  
 espresso bar and lounge  
 UCLA TDG Patio, 1st floor



**Charging Stations**  
 two in Centennial Prefunction Area, 1st floor  
 two in each Lounge, 2nd floor  
 three on Centennial Terrace, 3rd floor



**Lounges**  
 UCLA TDG Patio, 1st floor  
 2nd floor, North Wing  
 2nd floor, South Wing



**Pearl Cohen Poster Competition Awardees**  
 Entrepreneur, 2nd floor, South Wing



**Exhibitors**  
 1st floor  
 2nd floor, South Wing



**Institutional Partner Rooms**  
 City of Hope and USC  
 2nd floor, North Wing

**WIFI** 

**Network**  
 Luskin\_Meeting

**Password**  
 LCC2023

**#LABEST2023 | [tdg.ucla.edu](http://tdg.ucla.edu)**



---

## Changing the way cancer is treated.

Kite's singular focus is cell therapy  
to treat and potentially cure cancer.

Kite is a proud supporter of LABEST and its work  
to showcase bioscience innovation in Los Angeles.





📍 Centennial Ballroom, 1st Floor

## REGISTRATION OPENS

**7:30am REGISTRATION OPENS**  
South Courtyard/1st Floor

**BREAKFAST FEATURING THE CAPPUCCINO CONNECTION**  
Centennial Patio/1st Floor

**7:30am- 11:45am VISIT THE UCLA HEALTH HOMELESS HEALTHCARE COLLABORATIVE MOBILE CLINIC ON DISPLAY**  
The specially equipped vehicle provides much-needed services to unhoused people throughout Los Angeles.  
Main Entrance Driveway/1st Floor

## MORNING SESSION

Centennial Ballroom/1st Floor

Emcee: [Judy Fortin](#), Chief of Communications, [UCLA Health](#)

**8:30am WELCOMES BY**

- [UCLA Chancellor Gene Block](#)
- LABEST 2023 Innovator Sponsors  
Introduction by [Mark Wisniewski](#), Senior Director, Bio Pharmaceuticals, [UCLA TDG](#)
- [Jessica Droge](#), Vice President of Business Development, Head of Global Search & Evaluation, [Amgen](#)
- [Aliya Z. Omer](#), Vice President of Corporate Development & Head of Global Portfolio and Program Strategy, [Kite, a Gilead Company](#)

**8:45am “FIRESIDE CHAT” WITH THE UNIVERSITY OF CALIFORNIA BOARD OF REGENTS AND UCLA CHANCELLOR**  
The importance of academic research and intellectual property  
Introduction by [Amir Naiberg](#), AVC, CEO and President, [UCLA TDG](#)

- Moderated by [Judy Fortin](#)
- [UCLA Chancellor Gene Block](#)
- [Chair of the Board of Regents, Richard Leib](#)
- [Regent Lark Park](#)

**9:15am KEYNOTE ADDRESS**

Introduction by [Arie Beldegrun](#), Roy and Carol Doumani Chair in Urologic Oncology, UCLA

- [Dr. Albert Bourla](#), Chairman and CEO, [Pfizer](#)

**9:40am KEYNOTE ADDRESS**

Introduction by [Andrei Iancu](#), Partner, [Irell & Manella LLP](#)

- [Director General Daren Tang, WIPO](#)

**10:05am LA HOSPITAL LEADERS INNOVATING FOR FUTURE SUCCESS PANEL**

A panel discussion with Hospital CEOs from our long-standing LABEST partners in the Los Angeles area, covering challenges, accomplishments, and what the future has in store for Hospitals.

- Moderated by [Judy Fortin](#)
- Hosted by [Johnese Spisso](#), President of UCLA Health, CEO of UCLA Hospital System and Associate Vice Chancellor of UCLA Health Sciences

### Panelists include:

- [Dr. Elaine Batchlor](#), CEO, [MLK Community Healthcare](#)
- [Dr. Jeffrey Golden](#), Director, Burns and Allen Research Institute, Vice Dean for Research and Graduate Education, [Cedars-Sinai](#)
- [Mr. Chad Lefteris](#), CEO, [UCI Health](#)
- [Dr. Anish Mahajan](#), CEO and Chief Medical Officer, [Harbor-UCLA Medical Center](#)

# MAIN TRACK

## CONTINUED

Centennial Ballroom, 1st Floor

### 10:50am MEET THE LEADERS IN THE BUSINESS OF LIFE SCIENCES PANEL

A panel discussion with CEOs of Life Sciences companies discussing recent discoveries, new diseases and drug discoveries in the pipeline.

Introduction by [Dr. John Mazziotta](#), Vice Chancellor, UCLA Health Sciences, CEO, [UCLA Health](#)

- Moderated by [Arie Beldegrun](#), Roy and Carol Doumani Chair in Urologic Oncology, [UCLA](#), Director and Founder of [The UCLA Institute of Urologic Oncology](#), Co-Founder and Sr. Managing Director, [Vida Ventures](#), Executive Chairman and Co-Founder, [Allogene](#)

#### Panelists include:

- [Norbert Bischofberger](#), President and CEO, [Kronos Bio](#)
- [David Chang](#), President, CEO, and Co-Founder, [Allogene](#)
- [Mark Cobbold, MD, PhD](#), VP Discovery Oncology, Head of Oncology Cell Therapy, [AstraZeneca](#)
- [Aamir Malik](#), Chief Business Innovation Officer, Executive Vice President, [Pfizer](#)
- [Dennis J. Slamon, MD, PhD](#), Director of Clinical/Translational Research, [UCLA Jonsson Comprehensive Cancer Center](#)

### 12:00pm PEARL COHEN POSTER AWARDS ANNOUNCEMENT

This competition provides a unique opportunity to showcase the undergraduate and graduate bioscience research program to pharma and biotech industry leaders' entrepreneurs, and investors.

- Announced by [Michael Yamin](#), Scientific Advisor, [Pearl Cohen](#)

### PEARL COHEN POSTER CONTESTANTS

Entrepreneur/South 2nd Floor

11:30am- 5:30pm VIEW FIRST AND SECOND PLACE WINNING POSTERS

#### LUNCH

11:30am- EARLY LUNCH

12:45pm Open to General Attendees  
Legacy and Optimist, 2nd Floor

12:00pm- LUNCH | EXHIBITORS | NETWORKING

1:30pm Additional Lunch Locations Open to General Attendees:

- UCLA TDG Patio, 1st Floor
- Plateia, 1st Floor near Main Entrance

# UCLA TDG LEARNING LOUNGE

SPONSORED BY MCKOOL SMITH

 Optimist, 2nd floor, North Wing

## UCLA TDG LEARNING LOUNGE

Optimist, 2nd floor, North Wing

Sponsored by [MCKOOL SMITH](#)

### 1:00pm WELCOME BY

[Alfonso Chan](#), Principal, [McKool Smith](#)

### 1:01pm VENTURE CAPITAL PANEL

This panel aims to explore the opportunities, challenges, and evolving landscape for biotech venture creation in Los Angeles. The panel will focus on the Los Angeles biotech ecosystem.

- Moderated by [Josh Green](#), Chairman Emeritus, [National Venture Capital Association](#)

#### Panelists include:

- [Anurag Agarwal](#), Partner Life Science, [Osage University Partners](#)
- [Michael Fritz](#), Principal, [McKool Smith](#)
- [Sean Harper](#), Founding Managing Director, [Westlake Village BioPartners](#)
- [D.A. Wallach](#), General Partner & Co-Founder, [Time BioVentures](#)

### 2:10pm NETWORKING BREAK

### 2:30pm IMPROVING YOUR PRESENTATION SKILLS

Want to learn how to improve your skills and present like a pro? Join McKool Smith's Steven Pollinger for a workshop to help you craft your written and verbal remarks.

- [Steven J. Pollinger](#), Principal, [McKool Smith](#)

### 3:05pm INDUSTRY SPONSORED RESEARCH PANEL

An interactive discussion on the best practices for faculty to obtain Sponsored Research Agreements with the biopharma industry and how to maintain a successful collaboration.

- Moderated by [Angela Coxon](#), VP of Oncology Research, [Amgen](#)

#### Panelists include:

- [John Desjarlais](#), Executive Vice President, Research & Chief Scientific Officer, [Xencor, Inc.](#)
- [Mark Jurgens](#), Head of External Scientific Collaborations, [Kite, a Gilead Company](#)
- [Helen Kim](#), Executive Director, Head of Technology, Business Development, [Amgen](#)
- [Sanjay Mistry](#), Vice President, Venture Investments New Company Creation, [Johnson & Johnson Innovation, JJDC, Inc.](#)
- [Christina Ondrick](#), Principal, [McKool Smith](#)
- [Karla Zepeda](#), ISR Director, [UCLA TDG](#)
- [Ran Zheng](#), CEO, [Landmark Bio](#)

### 4:30pm INTELLECTUAL PROPERTY

Why do technology transfer offices exist?

Discussion between [UCLA TDG](#) Chief IP Officer, [Charan Arora](#) and [McKool Smith](#) Principals, [Steven J. Pollinger](#) and [Josh Budwin](#)

### 4:50pm PATENT LITIGATION PANEL

This panel aims to provide law firms' perspectives on patent litigation and share examples of cases that could've been avoided and how.

- Moderated by [Josh Budwin](#), Principal, [McKool Smith](#)

#### Panelists include:

- [Blair Jacobs](#), Principal, [McKool Smith](#)
- [Patrick Maloney](#), Senior Associate, [Armond Wilson LLP](#)
- [Mark Siegmund](#), Partner, [Cherry Johnson Siegmund James](#)
- [Peter Tong](#), Partner, [Russ August & Kabat](#)

# STARTUP ECOSYSTEM SHOWCASE

 Illumination, 2nd floor, South Wing

**Sponsored by [Abbott Construction](#) and [Breakthrough Properties](#)**

**Built by [The Lundquist Institute](#) and [Larta Institute](#)**  
Illumination, 2nd floor, South Wing

**1:45pm SHOWCASE CO-MODERATORS WELCOME BY**

- [Keith Hoffman, PhD](#), Senior Advisor for Business Development, [The Lundquist Institute](#)
- [Rohit K. Shukla](#), Founder & CEO, [Larta Institute](#)

**1:46pm SHOWCASE KEYNOTE**

- [Susie Harborth](#), Chief Business Officer, [Breakthrough Properties](#)

**2:00pm INCUBATOR AND STARTUP RESOURCES PANEL**

Select Los Angeles incubators will highlight their resources and top startups. They will participate in a panel discussion covering topics like: What is needed in our ecosystem? How can they improve? How can local government help us elevate Los Angeles on the map?

- Additional, Guest, Moderator: [Dave Whelan](#), CEO, [BioscienceLA](#)

**Panelists include:**

- [Danielle Bogdanowicz](#), VP of Business Operations & Strategy, [Biolabs at the Lundquist Institute](#)
- [Johnny Lam](#), VP Business Development, [Scale Health](#)
- [Nikki Lin](#), Director of Entrepreneurship & Commercialization, [Magnify at CNSI, UCLA](#)
- [Howard Xu](#), Director, Incubator Development and Programming, [Cal State LA BioSpace](#)

**2:45pm NETWORKING BREAK**

**3:00pm ADAPTIVE REUSE FOR BIOSCIENCE IN LOS ANGELES**

- [Marcella Ayala](#), Director of Business Development, [Abbott Construction](#)

**3:15pm REAL ESTATE AND BIOSCIENCE PANEL**

Real estate developers will discuss some challenges and successes they've experienced in aiding the growth of Los Angeles' startup ecosystem.

- Additional Guest moderator: [Larry Lantero](#), Vice President, [Abbott Construction](#)

**Panelists include:**

- [Marissa Goldberg](#), CEO, [Doheny Eye Institute](#)
- [Howard Kozloff](#), CEO and Founder, [Noblespace](#)
- [Peter Moglia](#), CEO and Co-Chief Investment Officer, [Alexandria Real Estate Equities, Inc.](#)
- [Nancy Moses](#), Principal, [Trammell Crow Company](#)
- [Chris Sinfield](#), Vice Chairman, [Cushman & Wakefield](#)

**4:15pm NETWORKING BREAK**

**4:30pm CITIES AND MUNICIPALITIES TO WATCH FOR**

Panelists will discuss what makes proposed projects appealing for city/government approval and what is needed to continue working together in making Los Angeles the next big bioscience hub.

- Additional, Guest Moderator: [Stephen Cheung](#), CEO, [LAEDC](#)

**Panelists include:**

- [Fran Fulton](#), Economic Development Manager, [Office of the City Manager, City of Torrance](#)
- [Teresa Garcia](#), Senior Project Manager, Economic Development Division, [Office of the City Manager, City of Pasadena](#)
- [Kelly LoBianco](#), Director, [LA County Department of Economic Opportunity](#)

# NUCLEATE AND UCLA PDA SHOWCASE

📍 Exploration, 2nd Floor, North Wing

## Built by [Nucleate](#)

Exploration, 2nd Floor, North Wing

### 2:00pm WELCOME AND INTRODUCTIONS TO NUCLEATE AND PDA

• [Nucleate Activator Program](#) Pitch Showcase. The program provides a proven and unparalleled competitive advantage to begin the lab-to-market journey. The primary program begins with a “mutual-matching” team formation phase, followed by workshops and mentor office hours, culminating in a final pitch showcase at LABEST.

#### Pitch Showcase Judges:

- [Aiden Aceves](#), Vice President of Investments, [Insight Partners](#)
- [Alan Block](#), Principal, [McKool Smith](#)
- [Paul Hughes](#), Executive Director of Research, [Amgen Inc.](#)
- [Seth Lieblich](#), Principal, [8VC](#)
- [Beverly Lu](#), Investment Manager, Health, [Emerson Collective](#)

### 2:10pm PITCH TEAM #1 - SERENITY

Wearable Stress Monitoring and Therapy

### 2:22pm PITCH TEAM #2 - SEMPER

Mammalian ratio-tunable polycistronic RNA expression platform for in vitro and in vivo delivery

### 2:34pm PITCH TEAM #3 - OSEM

Rapid prototyping with customizable tools to develop nanodrugs

### 2:46pm PITCH TEAM #4 - ACCELERATED MAGNETICS

Magnetic external control system for enhanced drug screening capabilities

### 2:58pm PITCH TEAM #5 - METABA

Novel adjunctive therapeutic for tuberculosis targeting metabolism

### 3:10pm AMGEN GOLDEN TICKET ANNOUNCEMENT

### 3:14 pm NETWORKING BREAK AND PITCH DELIBERATIONS

### 3:40pm IMPROVE YOUR PRESENTATION SKILLS

- [Judy Fortin](#), Chief of Communications, [UCLA Health](#)

### 4:20pm NETWORKING BREAK

### 4:35pm INDUSTRY SPONSORED RESEARCH PANEL

An interactive discussion on the best practices for postdocs to obtain Sponsored Research Agreements with the biopharma industry and how to maintain a successful collaboration.

- Moderated by [Tom Novak](#), CSO, [Autobahn Labs](#)

#### Panelists include:

- [Dan Gorman](#), Principal Scientist & Group Leader, [Merck](#)
- [Jessica Malloy](#), External Research Program Lead, [Kite, a Gilead Company](#)
- [Ryan Potts](#), Scientific VP of Research and Chair of R&D Postdoc Program, [Amgen](#)
- [Elizabeth Wu](#), Director, Early Innovation Partnering, [Johnson & Johnson Innovation](#)

# NUCLEATE AND UCLA PDA SHOWCASE

PROGRAMS ESPECIALLY FOR POSTDOCS AND GRADUATE STUDENTS

## COMPANY SUMMARIES

### **Serenity - Medical Devices/Digital Health**

**SUMMARY:** We have developed a wearable device that monitors physiological inputs correlating to psychological stress, which fits the PANAS questionnaire model to quantify stress in a continuous fashion. Using this information, our device will be able to personalize a therapeutic model for stress reduction via acoustics as thermal pads.

### **SEMPERTools/Techniques**

**SUMMARY:** Here we propose a novel solution, it allows for expression of multiple proteins from a single mRNA, and provides a user-friendly framework to arbitrarily and predictably tune translated product stoichiometry. We named this novel approach "Stoichiometric Expression of Messenger Polycistrons by Eukaryotic Ribosomes" (SEMPER). We aim to demonstrate that SEMPER can be used with engineered synthetic RNAs, which can be transfected directly in vivo. We would like to utilize this technology to form a company, which specializes in development and production of vaccines, therapeutics and engineered cell systems, which require precise control of production from genetically complex payloads.

### **OSEM - Medical Devices/Tools**

**SUMMARY:** OSEM is a rapid prototyping platform for nanodrugs. The OSEM platform employs proprietary micro-cartridges that enable scientists to easily automate different fluidic processes for nanodrug development, such as nanoparticle synthesis, nanoparticle concentration, and buffer exchange.

### **Accelerated Magnetics - Research Tools**

**SUMMARY:** Our technology turns the microscope sample stage into an electromagnet that, in conjunction with the magnetogel, allows us to study the effect of material changes on the cells and biological constructs grown within the material in-real time. Through functionalizing the microscope stage, we developed a technology that revolutionizes the cornerstone of scientific investigation.

### **METABA - Therapeutics**

**SUMMARY:** We plan to develop a novel Tuberculosis (TB) drug targeting a key enzyme in persister cells that will act as an adjunctive therapeutic, making the current antibiotic regimen more effective and shortening the length of treatment.

# LA BIOMANUFACTURING SHOWCASE

Legacy, 2nd Floor, South Wing

**Built by the California Institute for Regenerative Medicine (CIRM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)**

Legacy, 2nd Floor, South Wing

**2:30pm WELCOME BY**

- [Shyam Patel](#), Senior Director of Business Development and Alliance Management, [CIRM](#)

**2:32pm SHOWCASE KEYNOTE**

- [Mitra Cruz](#), VP of Manufacturing, Site Head – El Segundo Manufacturing Facility, [Kite, a Gilead Company](#)

**3:05pm WHAT TECHNOLOGY ADVANCEMENTS ARE NEEDED TO DELIVER ACCESSIBLE AND AFFORDABLE ADVANCED THERAPIES TO PATIENTS?**

- Moderated by [Gregory Theyel](#), PhD, Director, [Biomedical Manufacturing Network](#)

**Panelists include:**

- [Mohamed Abou-el-Enein](#), Executive Director, Joint USC/CHLA Cell Therapy Program, [USC](#)
- [Sylvain Roy](#), CTO, [ImmPACT Bio](#)
- [Dhruv Sareen](#), Executive Director, [Cedars-Sinai Biomanufacturing Center](#)
- [Dawn Ward](#), Associate Clinical Professor, [UCLA David Geffen School of Medicine](#)

**3:50pm NETWORKING BREAK**

**4:10pm HOW THE GROWING LA BIOMANUFACTURING ECOSYSTEM IS WELL POSITIONED TO ADVANCE CELL AND GENE THERAPY DEVELOPMENT**

- Moderated by [Gregory Theyel](#), PhD, Director, [Biomedical Manufacturing Network](#)

**Panelists include:**

- [Taby Ahsan](#), Vice President, Cell and Gene Therapy Operations, [City of Hope](#)
- [Gargi Ghosh](#), Associate Professor, Bioprocessing Program, [Keck Graduate Institute](#)
- [Elie Hanania](#), PhD, VP of Process Development Viral Vector Technologies, [Avid Bioservices](#)
- [Brianna Schoen](#), PhD, Sr. Scientific Director, [Charles River Laboratories](#), Cell Solutions

# NON-DILUTIVE FUNDING SEMINAR

📍 Enlightenment, 2nd Floor, South Wing

## Built by [BioscienceLA](#) and [Johnson & Johnson Innovation – JLABS](#), with [NIH](#)

Enlightenment, 2nd Floor, South Wing

Opportunities for faculty & startups to learn about non-dilutive funding opportunities, including SBIR awards, translational grant programs, and others.

- Opportunities to connect with representatives from select funding programs

### 3:00pm WELCOME & INTRODUCTIONS

- [Dave Whelan](#), CEO, [BioscienceLA](#)
- [LCDR Michael Banyas, USPHS, MPA, MA](#), SBIR Program Manager, [National Institute of Minority and Health Disparities](#)

### 3:10pm NIH FUNDING OPPORTUNITIES

- Explore priorities, opportunities, and strategies with leaders from NIH institutes – with a focus on how LA's diverse population represents a major priority for NIH funders and opportunity for LA founders
- Moderated by [Carlos Gutierrez](#), Chief Strategy Officer, [Larta Institute](#)

#### Panelists include:

- [Taryn Aubrecht, PhD](#), Health Program Specialist, [National Institute of Neurological Disorders & Stroke \(NINDS\)](#)
- [LCDR Michael Banyas, USPHS, MPA, MA](#), SBIR Program Manager, [National Institute of Minority and Health Disparities \(NIMHD\)](#)
- [Joshua Hooks, PhD](#), AAAS Science and Technology Policy Fellow, [National Institute on Aging \(NIA\)](#)
- [Jain Krotz, PhD](#), Health Scientist Administrator, [National Heart Lung and Blood Institute \(NHLBI\)](#)

*Note: Due to NIH travel schedules, participants are subject to change.*

### 4:00pm NON-DILUTIVE FUNDING STRATEGIES

Hear from experienced founders and advisors on best practices for non-dilutive funding

Moderator: [Stacy Feld](#), Regional Head, West North America, [Johnson & Johnson Innovation](#)

#### Panelists include:

- [Rupak Doshi](#), CEO, [OmniSync](#)
- [Earle Hager](#), Managing Partner, [The Neutrino Donut, LLC](#)
- [Alborz Mahdavi](#), VP, Protomer Technologies, [Eli Lilly and Company](#)
- [Joseph Schinaman, PhD](#), Chief Scientific Officer, [Petro Bio](#)

### 4:45pm AMGEN GOLDEN TICKET ANNOUNCEMENT

### 4:50pm ROUNDTABLE DISCUSSIONS

Meet our experts to explore specific ways that you can engage with them directly



# RESEARCH SHOWCASE A

📍 Artistry, 2nd Floor, South Wing

All Research Showcases are approximately 75 minutes each and may include a mix of

- Roundtable Discussions
- Panels
- Scientific Research Posters

## 1:43pm RESEARCH SHOWCASE: METABOLISM

Artistry, 2nd Floor, South Wing

Roundtable Discussions Led by [Orlan Shirihai](#), Professor of Medicine and Molecular and Medical Pharmacology & Chair and Professor, Endocrinology, Diabetes and Hypertension, UCLA

## 1:45pm LIVER DISEASE

- Discussion Leads:
  - [Rajat Singh](#), Professor of Medicine & Director of Program in Basic Liver Research, UCLA
  - [Joseph Pisegna](#), Professor, Division of Digestive Diseases, Department of Medicine and Human Genetics, David Geffen School of Medicine, UCLA
- **Panelist:** [Tari Suprpto](#), Director, Search & Evaluation (West), [Novo Nordisk](#)

## 2:30pm NETWORKING BREAK

## 2:45pm OBESITY & DIABETES

- Discussion Leads:
  - [Erik Dutson](#), Health Sciences Clinical Professor, David Geffen School of Medicine, UCLA
  - [Claudio Villanueva](#), Associate Professor, Department of Integrative Biology & Physiology, UCLA

## Panelists include:

- [Cynthia Hong](#), Director, Search & Evaluation, [Novartis](#)
- [Kelly Kaihara](#), Director, Life Science Tools & Diagnostics, [General Inception](#)
- [Tari Suprpto, PhD, RTTP](#), Director, Search & Evaluation (West), [Novo Nordisk](#)
- [Murielle Veniant-Ellison](#), Scientific Vice President, Global Research, [Amgen](#)

## 3:30pm NETWORKING BREAK

## 3:45pm MYOPATHIES

- Discussion Lead: [Andrea Hevener](#), Endowed Chair in Molecular/Cellular Endocrinology, UCLA
- **Panelist:** [Rachelle Crosbie](#), Professor, Department Chair, Integrative Biology and Physiology, UCLA

## 4:30pm NETWORKING BREAK

## 4:45pm CANCER & IMMUNO-METABOLISM

- Discussion Lead: [Andrew Goldstein](#), Assistant Professor in the departments of Molecular, Cell & Developmental Biology and Urology, UCLA
- **Panelist:** [Jim Johnston](#), CSO, [ImmPACT Bio](#)

# RESEARCH SHOWCASE B

📍 Centennial Ballroom AB, 1st Floor

## 1:45pm RESEARCH SHOWCASE: REGENERATIVE MEDICINE

Centennial Ballroom AB/1st Floor

Each researcher will introduce their work and the group will discuss the translation of stem cell research into clinical trials and the commercialization of stem cell findings.

- Led by [Thomas Rando](#), Director Broad Stem Cell Research Center, UCLA
- [Yvonne Chen](#), Associate Professor, UCLA
- [Denis Evseenko](#), Director of Skeletal Regeneration, [USC](#)
- [Don Kohn](#), Distinguished Professor, Microbiology, Immunology and Molecular Genetics, UCLA
- [Antoni Ribas](#), Professor of Medicine, Molecular and Medical Pharmacology, UCLA
- [Lili Yang](#), Associate Professor, Microbiology, Immunology and Molecular Genetics, UCLA

## 2:40pm POSTER SESSION

## 3:00pm NETWORKING BREAK

## 3:10pm RESEARCH SHOWCASE: IMMUNITY, INFLAMMATION, INFECTION, AND TRANSPLANTATION (I3T)

Centennial Ballroom AB/1st Floor

- Led by [Manish Butte](#), Professor, Pediatrics, UCLA  
[Dino Dicarlo](#), Professor/Vice Chair Grad Education, UCLA
- [Joe de Rutte](#), Co-Founder and CEO, [Partillion Bioscience](#)
- [Steven Jonas](#), Clinical Instructor, Pediatrics, UCLA
- [Negin Majedi](#), CEO, [Symphony Biosciences](#)
- [Andre Nel](#), Director of Research, [CNSI at UCLA](#)
- [Phil Scumpia](#), Assistant Professor-in-Residence, Medicine, UCLA
- [Lili Yang](#), Associate Professor, Microbiology, Immunology and Molecular Genetics, UCLA

## 4:25pm NETWORKING BREAK

## 4:35pm RESEARCH SHOWCASE: ONCOLOGY

Powered by  T R L  
BIOTHERAPEUTICS

Centennial Ballroom AB/1st Floor

[UCLA Jonsson Comprehensive Cancer Center](#)

### PI Spotlights:

- [Dr. Anna Wu](#), Chair and Professor, Department of Immunology & Theranostics, [City of Hope](#)
- [Dr. Xiuli Wang](#), Professor, Department of Hematology & Hematopoietic Cell Transplantation, [City of Hope](#)
- [James Turkson, PhD](#), Professor of Medicine, Associate Director for Diversity, Equity, and Inclusion, [Cedars Sinai](#)

## 4:50pm ACCELERATING INNOVATION IN ONCOLOGY PANEL

- Led by [Edward Garon](#), Professor, Medicine, UCLA
- [Steve Rosen](#), Provost & Chief Scientific Officer, [City of Hope](#)
- [Cristina Puig Saus](#), Assistant Adjunct Professor, Medicine, UCLA
- [David Shackelford](#), Associate Professor, Medicine, UCLA
- [Dennis J. Slamon, MD, PhD](#), Director of Clinical/Translational Research, [UCLA Jonsson Comprehensive Cancer Center](#)

## 5:30pm POSTER SESSION

# RESEARCH SHOWCASE C

Centennial Ballroom CD, 1st floor

## 1:45pm RESEARCH SHOWCASE: [CARDIOVASCULAR](#)

Centennial Ballroom CD/1st Floor

Speakers will present early technology all the way through technology that is ready for FDA submission

- Led by [Arjun Deb](#), Professor, Cardiology, UCLA
- [Hooman Allayee](#), Professor of Populations & Public Health Sciences and Biochemistry & Molecular Medicine, [USC](#)
- [Jau-Nian Chen](#), Professor, Molecular, Cell, and Developmental Biology, UCLA
- [Ahmed Ibrahim](#), Assistant Professor, [Smidt Heart Institute, Cedars Sinai](#)
- [Jake Lusic](#), Professor, Departments of Medicine, Human Genetics and Microbiology, Immunology & Molecular Genetics, UCLA
- [Julia Mack](#), Assistant Adjunct Professor, Medicine, UCLA

## 3:00pm NETWORKING BREAK

## 3:10pm RESEARCH SHOWCASE: [CLINICAL TRIAL ACCESS & ENROLLMENT](#)

Centennial Ballroom CD/1st Floor

- Led by [Arash Naeim](#), Professor-in-Residence, Medicine, UCLA
- [Sylvia Ferullo](#), Clinical Trial Navigator, Division of Hematology/Oncology, UCLA DGSOM
- [Maria Garcia-Jimenez](#), Health Sciences Clinical Instructor, UCLA; Director of Oncology Research, [Olive View - UCLA Medical Center](#)
- [Edward Garon](#), Professor, Medicine, UCLA
- [Zul Surani](#), Associate Director of Community Outreach and Engagement & Cancer Research Center for Health Equity, [Cedars-Sinai](#)
- [Maria Velez Velez](#), Fellow, Division of Hematology Oncology, UCLA
- [Kabir Yadav](#), Vice Chair for Research & Academic Affairs/Professor of Clinical Emergency Medicine, UCLA


## 4:25pm NETWORKING BREAK

## 4:35pm RESEARCH SHOWCASE: [NEUROSCIENCE](#)

Centennial Ballroom CD/1st Floor

Neurotechnologies: Exploring the Future of Implantable Neural Devices

- Led by [Nanthia Suthana](#), Associate Director, Neuromodulation Division, Jane and Terry Semel Institute for Neuroscience & Human Behavior, UCLA
- Brain to Body: Integrating implantable neurotechnologies and wearables
- [Tyson Aflalo](#), Scientist, [Convergent Research](#) Creating scientific tools to inform next-generation neural interfaces
- [Dejan Markovic](#), Professor, Samueli School of Engineering, UCLA
- The future of closed-loop neuromodulation technology
- [Maryam Shanechi](#), Professor and Viterbi Early Career Chair, Viterbi School of Engineering, [USC](#)
- Next-generation neurotechnology to treat mental health conditions



## **LABEST 2023 CLOSING RECEPTION**

**5:30pm** JOIN US FOR DRINKS, BITES,  
NETWORKING AND LIVE JAZZ!  
Centennial Terrace/3rd Floor

## **LABEST 2023 EXHIBITORS**

### **1st Floor (Open 8:00 am - 4:45 pm)**


A2 Bio  
Abbott Construction  
Amgen  
Appia Bio  
Breakthrough Properties  
Cal State LA  
Cedars Sinai  
Charles River  
Genentech  
ImmPACT Bio  
Johnson & Johnson Innovation  
Kite, A Gilead Company  
Landmark Bio  
Pearl Cohen  
UCLA Technology Development Group  
Xencor

### **2nd Floor (Open 11:30 am - 5:00 pm)**

Biocom CA  
BioscienceLA  
California Life Sciences  
California NanoSystems Institute at UCLA  
City of Hope (private room)  
Cvent  
Keck School of Medicine of USC (private room)  
LARTA Institute  
Lundquist Institute  
Merck  
UCLA Clinical and Translational Science Institute  
UCLA Health/Biodesign

## Treatment for Intellectual Disability Syndrome (Case ID: 2019-720 and 2020-777)

Inventors: Bill Lowry; Mike Jung; Bennett Novitch; Valerie Arboleda



### INNOVATION

Intellectual Disability (ID) affects more than 100 million people globally and imposes a heavy economic burden of \$14.7 billion annually on families and health systems. IDs, including Rett syndrome, Down syndrome, and fetal alcohol syndrome, are caused by mutations in epigenetic regulatory proteins. Recently these mutations have been implicated in causing the premature aging, or senescence, of neurons primarily located in the brain. However, drug development to treat such disorders has been significantly hindered by the difficulty in developing therapeutic compounds that are able to reach neurons in the brain. This is because of a tightly regulated cellular barrier that divides the vascular system from the central nervous system called the blood-brain barrier (BBB). Therefore, towards the development of curative drugs for IDs, crossing the BBB is of crucial importance.

UCLA researchers, led by Dr. William Lowry and Dr. Michael Jung, have discovered a library of compounds with the potential to reverse neuronal senescence and treat ID. Focusing on Rett syndrome for their studies, they developed Rett-derived human organoid models that allow screening of senescence inhibitors in the context of ID. Applying these models, they screened 45 molecules for senescence inhibition and identified 14 that successfully inhibited senescence, promoted dendritic branching, and restored brainwaves. Of those molecules, one novel compound was found to effectively penetrate BBB in-vivo in murine models.

These results indicate that compounds that reverse neuronal senescence and penetrate BBB could be effective for treating Rett syndrome. While other ID syndromes are caused by mutations in different epigenetic regulatory proteins, they all present with similar types of neuronal stress and similar neurological phenotypes. Therefore, the compounds identified here that reverse neuronal stress in models of Rett Syndrome could also alleviate ID syndrome symptoms in a wide variety of disorders.

### POTENTIAL APPLICATIONS

- ▶ Novel long-term therapy for ID
- ▶ Human organoid models can be utilized in high-throughput platforms to develop novel therapeutic strategies for ID and broader CNS diseases
- ▶ High therapeutic value of anti-senescence drugs towards treating age-related diseases such as Alzheimer's or atherosclerosis

### ADVANTAGES

- ▶ Compounds directly target the root cause of ID by reversing senescence
- ▶ Compounds serve an untapped therapeutic market with no currently approved treatment
- ▶ Organoids are physiologically relevant in vitro models

### For more information, contact:


William Decker or PJ Ward  
[william.decker@tdg.ucla.edu](mailto:william.decker@tdg.ucla.edu) or  
[peijejan.ward@tdg.ucla.edu](mailto:peijejan.ward@tdg.ucla.edu)

## Antisense oligonucleotide drugs (Case ID: 2018-717 and 2020-916)

Inventors: Feng Guo; Carrie Miceli; Yan Li; Florian Barthélémy

### Technology Overview

Lattice-assisted Crystallography for Rapid Determination of 3D Structure



- Target RNAs fused to a scaffold RNA
- Fusions crystallized similarly to scaffold
- 3D structures determined easily and rapidly
- RNA hairpin loop and RNA-ASO, RNA-small molecule drug complexes

### INNOVATION

RNA molecules play a critical role in the development of many diseases, such as cancers and RNA viral infections, making them excellent therapeutic targets. Technologies of targeting RNAs open new opportunities for therapeutic intervention, especially for genes that produce proteins previously deemed to be undruggable. Antisense oligonucleotides (ASOs) are single-stranded synthetic oligonucleotides that specifically bind target RNAs and elicit desired biological and therapeutic effects.

Recently, several ASO drugs have been approved by the FDA; however, current ASO Designs target RNA as a linear string i.e., 1D design strictly follows the rule of Watson-Crick (WC) base pairing. However, viral RNAs often fold into secondary and tertiary structures that can interfere with ASO hybridization. Key challenges of current ASO designs include variable binding affinity and specificity, relying on high-volume screening to identify leads, limitations in affinity and specificity resulting in narrow therapeutic windows, and the requirement for high concentration contributes to delivery problems.

UCLA researchers led by Dr. Feng Guo and Dr. Carrie Miceli have developed a three-dimensional (3D) structured-based method for designing ASOs. This new approach enables ASOs to bind with enhanced affinity and specificity; thus, allowing structured RNA to be targeted.

### APPLICATIONS

- ▶ Treat a host of diseases that are specifically regulated by almost any target RNAs

### ADVANTAGES


- ▶ Enhanced binding affinity and specificity to target RNAs
- ▶ Easy and rapid determination of 3D structures
- ▶ Wide applicability across a variety of diseases

### For more information, contact:

Dan-Oscar Antson or PJ Ward  
[dan-oscar.antson@tdg.ucla.edu](mailto:dan-oscar.antson@tdg.ucla.edu) or  
[peijean.ward@tdg.ucla.edu](mailto:peijean.ward@tdg.ucla.edu)

## In situ vaccination with CXCL9/10 gene modified dendritic cells for advanced stage non-small cell lung cancer (Case ID: 2018-912 and 2019-601)

Inventors: Steven Dubinett; Bin Liu; Raymond Lim



### INNOVATION

Lung cancer is the leading cause of cancer death worldwide, with a 5-year overall survival rate of 17% and 6% for metastatic disease. While lung cancers are responsive to PD-1 checkpoint blockade therapy, only 20% of patients respond to anti-PD-1 monotherapy due to primary, adaptive, or acquired resistance to the treatment. Thus, effective cancer immunotherapy requires methods to restore deficits in tumor antigen presentation and functional antitumor effector activities.

CCL21 is a secondary lymphoid chemokine that, upon binding to the CCR7 gene receptor, functions as a chemo-attractant for mature dendritic, naïve, and memory T cells, enhancing cell-mediated immunity against tumor cells. Intratumoral administration of CCL21 gene-modified dendritic cells (AdCCL21-DC) leads to increases of CD4+, CD8+, and CD11c+DEC205+ DCs infiltration of the tumor, decrease of immune-suppressive molecules in the tumor microenvironment, as well as reduction of tumor burden in the murine lung cancer model. More importantly, intratumoral administration of AdCCL21-DC also enhances CD8+ T cell infiltration and increased tumor PD-L1 expression in advanced non-small cell lung cancer (NSCLC) patients.

Researchers at UCLA have shown that advanced NSCLC patients with baseline PD-L1 expression benefit the most from anti-PD-1 treatment, suggesting responses to PD-1/PD-L1 blockade are more likely in the setting of tumor PD-L1 expression and a pre-existing T lymphocyte infiltration of the tumor. Indeed, UCLA researchers have shown that AdCCL21-DC and anti-PD-1 combination therapy outperforms both mono-therapies in syngeneic murine lung cancer models. Specifically, the combination therapy significantly enhances the cytolytic activity of tumor-infiltrating lymphocytes (TILs) against the tumor, accompanied by a significant reduction in tumor volume and tumor growth.

### APPLICATIONS

- ▶ Immunotherapy for NSCLC, melanoma, and other types of solid tumors

### ADVANTAGES


- ▶ Improve clinical response to anti-PD-1/PD-L1 therapy
- ▶ Boosts local and systemic immune responses
- ▶ Reduce tumor burden and tumor growth

### For more information, contact:

Tariq Arif  
Business Development Officer  
[tariq.arif@tdg.ucla.edu](mailto:tariq.arif@tdg.ucla.edu)

## Leveraging the Gut Microbiome to Combat Obesity and Food Addiction (Case ID: 2020-129)

Inventors: Tien Dong; Arpana Gupta



### INNOVATION

Obesity is a problem affecting millions with no widely available solutions. Obesity and its comorbidities pose a serious global health crisis. In 2016, about 2 billion adults, 18 years and older, were overweight. Of these, over 650 million were obese. This accounts for 39% of adults being overweight, and 13% being obese. These numbers are projected to continue to increase with rates as high as half of Americans being obese by 2030 and as high as 80% by 2050.

Food addiction is a major cause of obesity. Studies have shown that 30-50% of those who are overweight or obese have a food addiction. Food addiction is eating highly palatable foods (processed foods high in fat, sugar, and salt) when you are not hungry, as diagnosed using the Yale Food Addiction Scale. The diagnostic criteria for food addiction is based on the same criteria for other substance use disorders (i.e., alcohol, drugs, smoking). Food addiction affects the same regions of the brain as other addictive disorders.

A new pathway to combat both obesity and food addiction is through the brain-gut axis. UCLA researchers have shown there are 3 biological features of food addiction evident in the brain-gut axis. Using an untargeted metabolite assay examining >1000 different metabolites, food addiction was inversely associated with 1 metabolite: a neuroprotective metabolite called indolepropionate. Stronger connections in the brain's reward center, visible via MRI. Because indolepropionate is only created by our gut bacteria, UCLA researchers examined the microbiome of patients with food addiction and found a reduction in 3 protective bacteria.

### APPLICATIONS

- ▶ Therapeutic Drug target
- ▶ Non-invasive diagnostic screening tool to rule out obesity and type 2 Diabetes
- ▶ Obesity and Food Addiction Treatment
- ▶ Probiotics
- ▶ Biomarker screening

### ADVANTAGES

- ▶ A potential compound used to alter gut microbiome to progress obesity
- ▶ Develops a screen to identify patients with food addiction
- ▶ First of its kind compound for patients with food addiction


### For more information, contact:

Earl Weinstein  
Business Development Officer  
[earl.weinstein@tdg.ucla.edu](mailto:earl.weinstein@tdg.ucla.edu)



## A Hexokinase 2 Inhibitor to Treat Hepatocellular Carcinoma (Case ID: 2020-788)

Inventors: Peter Clark; Robert Damoiseaux; Varghese John; Richard Finn



### INNOVATION

Hepatocellular carcinoma (HCC) has a 5-year survival rate of <15%. The current standard of care for HCC includes chemotherapies such as atezolizumab/bevacizumab, sorafenib/Lenvatinib, and/or immunotherapy regimen of nivolumab, pembrolizumab, nivolumab + ipilimumab). However, none of the current therapies have biomarkers to allow for patient selection. Thus, new therapies are needed to treat HCC. Hexokinase 2 (HK2) is a well-validated target in HCC i.e., up to 40% of HCC express high levels of HK2, which is required for the growth of these tumors.

UCLA researchers led by Dr. Peter Clark have developed a small molecule inhibitor of Hexokinase 2 (HK2), an essential enzyme in over 40% of HCC, to treat HCC. They have developed and validated a high-throughput assay (based on a commercial assay) for identifying small molecule inhibitors of HK2. The cellular screen allows them to identify compounds that block HK2 activity through mechanisms other than direct binding to the enzymatic pocket.

### APPLICATIONS

- ▶ Precision medicine approach i.e., enables targeting of select patient-population that would benefit from targeting Hexokinase 2
- ▶ 18F-FDG PET can be used to non-invasively measure hexokinase activity in patient tumors

### ADVANTAGES


- ▶ Identifies selective hexokinase inhibitors
- ▶ The assay is reproducible and precise
- ▶ Targets an orthogonal pathway to current therapies
- ▶ Cost-effective

### FOR MORE INFORMATION, CONTACT:

Dan-Oscar Antson or PJ Ward  
[dan-oscar.antson@tdg.ucla.edu](mailto:dan-oscar.antson@tdg.ucla.edu) or  
[peijean.ward@tdg.ucla.edu](mailto:peijean.ward@tdg.ucla.edu)

## Targeting RNA Binding Proteins in Cancer Cells (Case ID 2019-831)

Inventors: Dinesh Rao; Neil Garg; Robert Damoiseaux



### INNOVATION

Chromosomal rearrangements of mixed-lineage leukemia (MLL/KMT2A) gene are recurrently found in a subset of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and rarely in acute leukemia of ambiguous lineage. Despite recent advances in therapeutic approaches, patients with MLL-rearranged (MLLr) leukemia have poor outcomes, a high risk of relapse, and show resistance to novel targeted therapies.

UCLA researchers led by Dr. Dinesh Rao have identified a novel RNA binding protein, IGF2BP3, which is overexpressed in multiple cancer types and not expressed in normal tissues. Preclinical studies conducted by Dr. Rao and colleagues showed that:

- ▶ On knocking out IGF2BP3 gene expression in-vitro and in-vivo
  - Leukemic cell growth decreased in-vitro
  - MLL-driven leukemia reduced, which increases survival in-vivo
  - Normal hematopoiesis was not affected in-vivo
- ▶ Overexpression of IGF2BP3 gene in vivo led to an increase in white blood cell (WBC) lineages

The above suggests that IGF2BP3 played a critical role in B acute lymphoblastic leukemia (B-ALL) with MLL translocations, thus making IGF2BP3 an important therapeutic target for rB-ALL MLL translocations. Dr. Rao and colleagues are currently developing a novel small molecule IGF2BP3 inhibitor that targets a pathway orthogonal to existing therapies, making it ideal for patients with refractory disease.

### APPLICATIONS

- ▶ Orthog can be used to treated patients with refractory disease

### ADVANTAGES

- ▶ Cost-effective
- ▶ Greater ease of adoption than existing therapies (i.e., CD-19 CAR-T)

### For more information, contact:


Dan-Oscar Antson or PJ Ward  
[dan-oscar.antson@tdg.ucla.edu](mailto:dan-oscar.antson@tdg.ucla.edu) or  
[peiJean.ward@tdg.ucla.edu](mailto:peiJean.ward@tdg.ucla.edu)

## Novel Antiviral Compounds to Treat Enterovirus Infections (Case ID: 2012-260 and 2015-829)

Inventors: Paul Krogstad; Michael Jung; Jun Zuo; Yanpeng Xing

### Technology

- Pyrazole-pyridine analogues that have been chemically modified for potent antiviral activity



### INNOVATION

Researchers in UCLA's Department of Molecular & Medical Pharmacology and Department of Chemistry & Biochemistry have used a rapid, live virus assay to help design and test potent enterovirus inhibitors. The compounds are unlike any previously described inhibitors of EV replication, and exhibit very potent activity against coxsackievirus B. Using these novel analogues, the researchers designed and synthesized several EV growth inhibitors that exhibit more potent activity and broader spectrum of activity than currently available therapeutics. The antiviral agents can be altered and expanded to other members of picornavirus family, or other viruses with similar replication strategies. These antiviral agent derivatives could become the basis for development of medications to combat different classes of viral infections.

### APPLICATIONS

- ▶ Treatment of various EV infections
- ▶ Development of antiviral agents for treatment of other viruses

### ADVANTAGES

- ▶ Compounds exhibit potent antiviral activity
- ▶ Compounds exhibit a broad range of antiviral activity
- ▶ Compounds are applicable to large number of medically relevant enteroviruses
- ▶ Antiviral analogues have the potential to be expanded to treat other families of viruses

### FOR MORE INFORMATION, CONTACT:

William Decker or Peijean (PJ) Ward  
[william.decker@tdg.ucla.edu](mailto:william.decker@tdg.ucla.edu) or  
[Peijean.ward@tdg.ucla.edu](mailto:Peijean.ward@tdg.ucla.edu)

# LEADING THE NEXT REVOLUTION

in cell therapy through the development  
of allogeneic chimeric antigen receptor  
T cell (AlloCAR T™) products for cancer.



[allogene.com](http://allogene.com)

## AUTOBAHN LABS

**Partner with Autobahn Labs  
to realize the potential of  
your scientific research**

- ❖ Up to \$5 million invested per project
- ❖ De-risking early-stage to preclinical development candidates
- ❖ Industrialized drug discovery capabilities with access to over 3,000 scientists


For additional information contact [tom@autobahn-labs.com](mailto:tom@autobahn-labs.com)



**GLOBAL  
KNOWLEDGE.  
SPECIALIZED  
EXPERIENCE.**

**FOLEY HOAG IS PLEASED TO SUPPORT LABEST 2023**

At Foley Hoag, our immersion in the life science industry enables us to provide the clear and sound counsel you need, helping you realize every advantage.



Johnson & Johnson INNOVATION

A great idea can  
come from anywhere

Partnering to accelerate innovation:



840+

companies in our global  
incubator network



940+

collaborations and  
investments since 2013



\$5.6B+

deployed globally  
since 2013

Let's connect: [www.jnjinnovation.com](http://www.jnjinnovation.com) | [@njinnovation](https://twitter.com/jnjinnovation)



We believe that you  
deserve great local news.

LAist is a local and fact-based  
nonprofit news source.

[LAist.com](http://LAist.com)



# McKool Smith

## The Leader in Intellectual Property Litigation



Austin Dallas Houston Los Angeles Marshall New York Washington, D.C.

[www.mckoolsmith.com](http://www.mckoolsmith.com)

*Attorney Advertising. Prior results do not guarantee a similar outcome.*

 NORTON ROSE FULBRIGHT

## On the cutting edge.

Norton Rose Fulbright is a proud sponsor of the UCLA Bioscience Innovation Day.

Consistently ranked among the top life sciences firms in the US, Norton Rose Fulbright's extensive pharmaceutical and biotechnology practice includes practitioners who are the trusted advisors for academic medical centers, research hospitals and universities, as well as biomedical and life sciences companies of all sizes for a wide variety of their legal needs.

Clients count on us to provide the forward-thinking perspective necessary to bring creative solutions to ongoing and new challenges and trends.

Best Law Firms, Tier 1 and national rankings for  
intellectual property, patent, and healthcare law  
*US News & World Report and Best Lawyers, 2023*

IAM Patent 1000, leading  
international patent practice  
*Intellectual Asset Management, 2022*

Law around the world  
[nortonrosefulbright.com](http://nortonrosefulbright.com)

# PEARL COHEN

New York - Los Angeles - Boston

## Your **Global** Partners in the **Business of Innovation**

Our Life Science Group represents biotechnological, chemical, pharmaceutical, nanotechnology, and medical technologies.

At Pearl Cohen, the convergence of science, technology, law and business is at your service.



**Mark Cohen, Partner**  
**Chair of Life Science Group**  
mcohen@pearlcohen.com

[www.pearlcohen.com](http://www.pearlcohen.com)

T  R L  
B I O T H E R A P E U T I C S



## Engineering Proteins to Make Better Medicines



At Xencor, we are engineering new protein technologies and advancing a broad clinical portfolio of bispecific antibodies and cytokines to treat patients with cancer and autoimmune diseases.



Collaboration, creativity, flexibility and resilience are critical to our culture of scientific discovery.

Learn more about us, potential collaborations between UCLA and Xencor, and career opportunities at our booth at LABEST 2023 and at [xencor.com](http://xencor.com).

Pasadena | San Diego



## A RADICAL NEW WAY TO TREAT SOLID TUMORS

A2 Bio's proprietary Tmod™ platform has the ability to distinguish tumor from normal cells, addressing barriers to solid tumor treatment

[www.A2Bio.com](http://www.A2Bio.com)



**ABBOTT**  
CONSTRUCTION  
BUILT TRUE. BUILT TOGETHER.



A Life Sciences & Healthcare contractor.

Give us a call.  
Discover a better way to build.

LOS ANGELES | SEATTLE | TACOMA  
[ABBOTTCONSTRUCTION.COM](http://ABBOTTCONSTRUCTION.COM)



**LANDMARK BIO**

Transforming Development & Industrialization of Advanced Therapies



World-Class Solutions  
**Close to Home**

Get to market faster with our research-ready solutions

- Human immune cells for basic research and cell and gene therapies
- Humanized and immunodeficient research model portfolio with VAF/Elite® health status
- CRADL® turnkey vivarium rental space with expert *in vivo* services



charles river

**MAKE THE IMPOSSIBLE  
A REALITY**

Cvent's innovative event tech brings the biggest, boldest event ideas to life.

*(Take LABEST for example)*

Learn more at: [cvent.com/wgyc](http://cvent.com/wgyc)



ANY EVENT. EVERY EVENT.  
**cvent**  
WE'VE GOT YOU COVERED.

**GATES & COOPER LLP**  
INTELLECTUAL PROPERTY LAW

# Caltech



Using the power of  
leading-edge science  
to save and improve  
lives around the world



Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.  
All rights reserved. US-NON-11404 08/22

Science  
demands  
diversity.




[GENE.COM/DIVERSITY-INCLUSION](https://www.gene.com/diversity-inclusion)

**Genentech**  
A Member of the Roche Group

# IMPACT BIO

ENGINEERING  
THE FUTURE OF  
CAR T-CELL  
THERAPIES



[ImmPACT-Bio.com](https://www.immpact-bio.com)



# POWERING LA'S INNOVATORS

Our interdisciplinary Life Sciences team supports innovators and entrepreneurs across Southern California as they pursue critical biomedical breakthroughs and push toward the next transformative therapies.



300 South Grand Ave, Suite 4100  
Los Angeles, CA 90071  
nixonpeabody.com | @NixonPeabodyLLP



**CSL is a leading global biotech company that develops and delivers innovative biotherapies that help people with life-threatening medical conditions live full lives.**

At CSL we believe that for innovation to be fast tracked, we need to partner with the brightest minds in the sector. We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and we collaborate and work with external organizations that have unique technologies, assets and equipment, to address patients' unmet needs around the globe.



APPIA BIO

## MAKING WAVES

IN CELL THERAPY



JOIN A TEAM THAT  
**INSPIRES YOU.**



# ACCELERATING DISCOVERIES

## TO PREVENT AND CURE CANCER

The UCLA Jonsson Comprehensive Cancer Center is a proud sponsor of the **Los Angeles Bioscience Ecosystem Summit 2023**. We're pleased to partner with the UCLA Technology Development Group as we work together to advance the latest scientific breakthroughs in bioscience, and help bring tomorrow's new generation of critical cancer therapies to patients.



LEARN MORE AT  
[CANCER.UCLA.EDU](http://CANCER.UCLA.EDU)



A history of support as you guide your hematology patients  
Our product portfolio may help

**ADVATE**  
[Antihemophilic Factor (Recombinant)]

**ADYNOVATE**  
[Antihemophilic Factor (Recombinant), PEGylated]

**vonvendi**  
[von Willebrand factor (Recombinant)]

**Obizur**  
[Antihemophilic Factor (Recombinant), Porcine Sequence]

**RECOMBINATE**  
[Antihemophilic Factor (Recombinant)]

**RIXUBIS**  
[COAGULATION FACTOR IX (RECOMBINANT)]

**FEIBA**  
[anti-inhibitor coagulant complex]

Please see accompanying **FEIBA full Prescribing Information**, including **BOXED WARNING** on Embolic and Thrombotic Events.



©2023 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA® and the TAKEDA Logo® are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. ADVATE, ADYNOVATE, FEIBA, OBIZUR, RECOMBINATE, RIXUBIS, and VONVENDI and the associated logos are trademarks or registered trademarks of Baxalta Incorporated, a Takeda company. US-XMP-1979v1.0 09/22

### SUPPORTING COMMUNITIES



Proud Sponsor of  
**Great Causes**

**PERKINS COIE** is proud to support the UCLA Technology Development Group and the LA Bioscience Ecosystem Summit 2023.

[PerkinsCoie.com](http://PerkinsCoie.com)

Perkins Coie LLP Lawyer Advertising



## BioscienceLA

Catalyzing life sciences innovation in Los Angeles

**#LongLA Congratulations on LABEST 2023!**



As a catalyst for innovation, BioscienceLA seeks to enable diversity, amplify science, and accelerate collaboration

BioscienceLA is proud to be a partner to TDG – on LABEST, the MedTech Partnering Conference, and other programs and events

From the BioFutures Internship Program to BioscienceLA.TV, the Leadership Catalyst Program to our Collaboration Hub, we're here to support the greater LA community

### BIOSCIENCELA FOUNDING SPONSORS



[biosciencela.org](http://biosciencela.org) | [@biosciencela](https://twitter.com/biosciencela)

**BioscienceLA**



## We are the Advocate for Life Science in California

### Representing over 1,700 members of the life science community statewide

Biocom California is the indisputable leader in accelerating life science in California. We accelerate our members' success by advocating for innovation, removing barriers to doing business, and connecting people, talent, and capital.

Learn more at [www.biocom.org](http://www.biocom.org)



## Research and Development

We are rapidly turning breakthrough therapies into lifesaving treatments.



- We have three on-site cGMP manufacturing facilities.
- We have a powerful in-house research incubator.
- We were awarded \$214 million in research grants last year.
- We have filed 145 IND applications.
- We earned \$2.9 billion in royalties and licensing over the past decade.
- We hold more than 450 patents for technology invented here.

Find out more at [CityofHope.org/gmp-manufacturing-facility](http://CityofHope.org/gmp-manufacturing-facility).

## Keck School of Medicine of USC


### MESH Strategic Partnerships

We enable transformative innovation through the power of partnership with personalized services for USC faculty and industry.

## Let's Connect and Collaborate!

Partnering Strategies

Access to Resources



Involvement with Researchers

Economic Development

Involvement with Centers and School


Visit the USC MESH room on the second floor <https://keck.usc.edu/mesh-academy/get-started/>



# Cedars Sinai



**Accelerating Ideas  
Into Therapies.**



With \$5.5B in funding, the **California Institute for Regenerative Medicine (CIRM)** de-risks regenerative medicine therapy development from discovery through pivotal clinical trials.

**Explore Funding Opportunities**



**Join Our Industry Alliance Program**



We partner with industry to accelerate development and commercialization of CIRM-funded regenerative medicine therapies.



**Accelerate With Us | [www.cirm.ca.gov](http://www.cirm.ca.gov)**



Learn about the **California NanoSystems Institute** and the **Magnify Incubator** as we participate in the **Los Angeles Bioscience Ecosystem Summit Twenty23**

**INNOVATE**

Promoting nanoscience research at interfaces between disciplines

**DISCOVERY**

NanoSciences, NanoMaterials  
NanoTechnologies

**TRANSLATION**

StartUp Ventures, Industry Alliances, Licensing & Tech Transfer

**Team Science Platform**

Address grand challenges in health & biomedicine, energy, IT, environment

**Technology Platforms**

Open-access Centers provide and develop leading-edge technologies & instrumentation

- Device nanofabrication, epitaxy
- Cellular, molecular, atomic imaging
- High-throughput screening

**Entrepreneurship Platform**

15,000 sq. ft. wet lab & office incubation space for UCLA start-ups

Currently incubating 29 start-up companies

**INCUBATE**

Translating discoveries into commercial enterprises

**ACCELERATE**

Educating the next generation of scientists and engineers

Visit us at: [WWW.CNSI.UCLA.EDU](http://WWW.CNSI.UCLA.EDU) | [WWW.MAGNIFY.CNSI.UCLA.EDU](http://WWW.MAGNIFY.CNSI.UCLA.EDU)



**UCLA CTSI**  
Grant # UL1TR001881

*Proud sponsor of LABEST*

- Clinical and Translational Research Centers
- Coordinator Support for Clinical Trials
- Regulatory Support
- Clinical Research Finance Expertise
- Biostatistical Consults
- Staff and PI Training in Clinical Research
- Facilitation of EHR Data for Cohort Finding
- FDA IND/IDE Support
- Data Analytics and Med-Tech Innovation
- Innovate Approaches to Patient Recruitment

Sign up for the CTSI newsletter  
[ctsinews@mednet.ucla.edu](mailto:ctsinews@mednet.ucla.edu)

UCLA Clinical and Translational Science Institute  
[www.ctsi.ucla.edu](http://www.ctsi.ucla.edu)



**Heal.LA**

**Initiative**

Improving the health and wellness of Los Angeles County & beyond.

Powered By:



**Heal.LA is a new collaborative initiative to improve the health & wellness of Los Angeles County and beyond.**

Applications are now open for our BioScience & Healthcare Accelerator Program.

Scan the code or visit [Larta.org/Heal](http://Larta.org/Heal) for more information.





## 70 Years of Saving Lives. Daily.

At The Lundquist Institute, we are committed to moving biomedical research forward and saving lives around the world.

The Lundquist Institute invites you to learn more and/or donate at: <https://lundquist.org/>



**NIIMBL** \* The National Institute for Innovation in Manufacturing Biopharmaceuticals

## ARE YOU A CHANGEMAKER?

Join NIIMBL, the fastest growing consortia in the U.S. dedicated to biopharmaceutical manufacturing. Equipped to lead, invest, train, create, and ultimately, innovate, NIIMBL joins industry, academia, government agencies, and non-profits to advance the biopharmaceutical manufacturing industry in the United States.

### Contribute to transformations in...

- Process Intensification
- Big Data
- Viral Vector Manufacturing
- Vaccines Manufacturing
- Workforce Development

**\$111M**  
INVESTED IN  
TECHNOLOGY  
& WORKFORCE  
DEVELOPMENT  
PROJECTS

**>200**  
MEMBER  
ORGANIZATIONS

LEARN MORE AT [NIIMBL.ORG](http://NIIMBL.ORG)



## We empower biotech leaders

Nucleate is a free and collaborative student-run organization that facilitates the formation of pioneering life sciences companies.



Learn more at [nucleate.xyz](http://nucleate.xyz)



**UCLA PDA (Post Doc Association)** is a volunteer organization run by postdocs that aims to build, enrich, and support the larger community of postdoctoral scholars at UCLA

**POSTDOCTORAL  
ASSOCIATION**  
at UCLA

[pda.ucla.edu](http://pda.ucla.edu)





UCLA Technology Development Group are the producers of LABEST 2023. This is the fifth year of the conference and we are proud to see how it has grown. LABEST brings together bioscience researchers, faculty, industry and investors for a day of conversation and connection. Thank you for attending the event.

## FACTS & FIGURES

UCLA ranks among the nation's Top Five institutions in research funding.

### UCLA TDG FY2022

**20**

Start Ups

**32**

Exclusive Licenses

**338**

Invention Disclosures

**\$70M**

Industry Sponsored Research Awards

### UCLA RANKED

**#9**

Heartland Forward Tech Transfer & Commercialization Report

**#12**

Pitchbook Startup Founders

### UCLA TECHNOLOGY DEVELOPMENT GROUP SCOPE OF ACTIVITIES

Commercially evaluating new technologies

Determining patentability and commercial value

Prosecuting patents

Marketing and licensing inventions

Facilitating UCLA faculty startups

Engaging industry to facilitate research collaboration

Negotiating license agreements and Material Transfer Agreements

Receiving and distributing royalties and other income to the inventors, UCLA campus and its departments

Producing the UCLA MedTech Partnering Conference and the Los Angeles Bioscience Ecosystem Summit (LABEST)

PRODUCED BY:



UCLA TECHNOLOGY DEVELOPMENT GROUP (TDG) promotes UCLA innovation, research, education and entrepreneurship to benefit society. Working with UCLA TDG helps facilitate the translation of UCLA discoveries into new products and services that create economic value to support UCLA's scholarly and educational missions. The UCLA TDG office manages a large portfolio of technologies and license agreements and has a rich history of startup company formation.

**CONNECT WITH UCLA TDG:**

Visit us at [tdg.ucla.edu](http://tdg.ucla.edu)

Contact us at [marketing@tdg.ucla.edu](mailto:marketing@tdg.ucla.edu)

Connect with us @UCLATDG



**#LABEST2023**

UCLA Technology Development Group  
10889 Wilshire Blvd. Suite 920  
Los Angeles, CA 90095  
310-794-0558

